Budesonide-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEBudesonideCat.No.:HY-13580CASNo.:51333-22-3分⼦式:C₂₅H₃₄O₆分⼦量:430.53作⽤靶点:GlucocorticoidReceptor作⽤通路:Immunology/Inflammation储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:215mg/mL(499.38mM;Needultrasonicandwarming)MassSolvent1mg5mg10mgConcentration制备储备液1mM2.3227mL11.6136mL23.2272mL5mM0.4645mL2.3227mL4.6454mL10mM0.2323mL1.1614mL2.3227mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(4.83mM);Clearsolution1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(4.83mM);Clearsolution3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(4.83mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性Budesonide⼀种吸⼊型糖⽪质类醇，具有⼝服活性的糖⽪质激素受体(glucocorticoidreceptor)激动剂。Budesonide可减少肺部肿瘤的⼤⼩，逆转DNA低度甲化并调节因的mRNA表达。Budesonide⼀种可以⽤于哮喘的抗炎药。体外研究Budesonideisselectiveforhumanglucocorticoidreceptor(hGR;EC50=45.7pM)overmineralocorticoidreceptors(EC50=7,620pM)inCV-1cells[1].Budesonide(30ꢀminpriortoLPS)suppressestheactivationoftheNLRP3inflammasomebyLPS(100ꢀng/mL)plusATP(5ꢀmM)inmacrophages(RAW264.7cells)[2].体内研究Budesonide(2.0mg/kg;orallyviatheirdiet;at2,7and21dayspriortokilling)decreasesthesizeoflungtumors[3].Budesonide(0.5ꢀmg/kg;intranasaladministration1ꢀhbeforeLPSinjection(5ꢀmg/kg))pretreatmentdramaticallyattenuatespathologicalinjuryandreducespathologicalscoresinmicewithALIinadultmaleC57BL/6mice[2].AnimalModel:FemalestrainA/Jmiceat8weeksofage[3]Dosage:2.0mg/kgAdministration:Orallyviatheirdiet;at2,7and21dayspriortokilling(27weeks)Result:Reducedthesizeofthelungtumorsafter2daysandrapidlydecreasedthesizeoflungtumors,reversedDNAhypomethylationandmodulatedmRNAexpressionofgenes.户使⽤本产品发表的科研⽂献•MilMedRes.2022Jan29;9(1):7.•JControlRelease.2019Dec28;316:66-78.•DrugTestAnal.2020Aug27.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].ClaudiaGrossmann,etal.TransactivationviatheHumanGlucocorticoidandMineralocorticoidReceptorbyTherapeuticallyUsedSteroidsinCV-1Cells:AComparisonofTheirGlucocorticoidandMineralocorticoidProperties.EurJEndocrinol.2004Sep;151(3):2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE[2].LiangDong,etal.IntranasalApplicationofBudesonideAttenuatesLipopolysaccharide-InducedAcuteLungInjurybySuppressingNucleotide-BindingOligomerizationDomain-LikeReceptorFamily,PyrinDomain-Containing3InflammasomeActivationinMice.JImm[3].MichaelAPereira,etal.ModulationbyBudesonideofDNAMethylationandmRNAExpressioninMouseLungTumors.IntJCancer.2007Mar1;120(5):1150-3.McePdfHeightCaution:Producthasnotbeenfully